title: Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis.
abstract: BACKGROUND
  Newer therapies provide high levels of skin clearance in patients with moderate to severe psoriasis. However, insufficient evidence exists on the impact of total skin clearance from the patient's perspective.
  
  
  OBJECTIVE
  To examine effects of total skin clearance on health-related quality of life (HRQoL) and psoriasis symptom severity in subjects with moderate to severe psoriasis.
  
  
  METHODS
  Pooled data from a phase 2 dose-ranging trial in psoriasis using brodalumab (antibody to interleukin-17 receptor A) were used to compare subjects with static physician global assessment (sPGA) 1 versus sPGA 0 and subjects with Psoriasis Area and Severity Index (PASI) 75 to <100 versus PASI 100 at week 12 based on no impairment in Dermatology Life Quality Index (DLQI = 0) and no psoriasis symptoms (Psoriasis Symptom Inventory = 0).
  
  
  RESULTS
  Of subjects with sPGA 0 (clear) and 1 (almost clear), 61.4% and 45.7% had a DLQI = 0 (p = 0.15), and 65.5% and 32.6% had a Psoriasis Symptom Inventory = 0 (p = 0.001), respectively. Significantly more subjects with sPGA 1 continued to report itching, redness, scaling, and flaking compared to subjects with sPGA 0. Similar results were observed based on PASI score.
  
  
  CONCLUSIONS
  A higher proportion of subjects with total skin clearance reported no impairment in HRQoL and no psoriasis symptoms than those who were almost clear.
authors: Amgen Inc. , Thousand Oaks, CA , USA and.
authors: Hema N
authors: HN
authors: Viswanathan
authors: Dina
authors: D
authors: Chau
authors: Cassandra E
authors: CE
authors: Milmont
authors: Wenjjing
authors: W
authors: Yang
authors: Ngozi
authors: N
authors: Erondu
authors: Dennis A
authors: DA
authors: Revicki
authors: Paul
authors: P
authors: Klekotka
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011537:Pruritus / Q000209:etiology; D011565:Psoriasis / Q000473:pathology*; D011788:Quality of Life; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C571216:brodalumab
keywords: Brodalumab; dermatology life quality index; health-related quality of life; patient-reported outcomes; plaque psoriasis; psoriasis area and severity index; psoriasis symptom inventory; static physician global assessment